"instanceType","uuid:ID","description","id","rationale","name","label"
"StudyDesign","c4b8bb63-2053-4f89-b3a0-990c85e42ca6","The main design for the study","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1",""
